Acrivon Therapeutics, Inc. (ACRV:NASDAQ) closed at $1.76 on October 15, 2026, up 2.33% on the day. The stock trades 50.6% below its 52-week high of $3.56 and 38.6% above its 52-week low of $1.27. Over the past year, it lost 9.0%. Acrivon Therapeutics, Inc. is part of the Health Care sector.
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| -9.47% | -6.01% | -1.71% | -7.53% | -8.99% |
In 252 trading sessions since October 14, 2025, ACRV closed higher on 115 days (46%). Its best day was January 6, 2026 (+31.44%) and its worst was January 8, 2026 (-34.58%). The stock moved 10% or more in a single session 9 times. It opened at least 5% above the previous day's high 3 times.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Company matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
Find more stocks like ACRV with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.